Hyloris Buys Out Maxigesic IV Royalty Rights From Alter Pharma

As Both Companies Sign A €5.75m Renegotiated License Agreement

 
• By Akriti Seth
  
Royalties
Hyloris foregoes all past commitments and future royalty obligations to Alter for Maxigesic IV • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business